References:
1. Biancari F, Mikkola R, Heikkinen J, Lahtinen J, Airaksinen KEJ, Juvonen T. Estimating the risk of complications related to re-exploration for bleeding after adult cardiac surgery : a systematic review and meta-analysis. Eur J Cardiothorac Surg . 2012;41(1):50-55. doi:10.1016/j.ejcts.2011.04.023
2. Vivacqua A, Koch CG, Yousuf AM, Nowicki ER, Houghtaling PL, Blackstone EH, et al. Morbidity of Bleeding After Cardiac Surgery : Is It Blood Transfusion , Reoperation for Bleeding , or Both? Ann Thorac Surg . 2011;91(6):1780-1790. doi:10.1016/j.athoracsur.2011.03.105
3. Koch C, Li L, Duncan A, Mihaljevic T, Cosgrove D, Loop F. Morbidity and mortality risk associated with red blood cell and blood- component transfusion in isolated coronary artery bypass grafting. Crit Care Med . 2006;34(6):1608-1616. doi:10.1097/01.CCM.0000217920.48559.D8
4. Schumer EM, Chaney JH, Trivedi JR, Linsky PL, Williams ML, Slaughter MS. Emergency Coronary Artery Bypass Grafting: Texas Hear Inst J . 2016;43(3):214-219.
5. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. AHA Statistical Update Heart Disease and Stroke Statistics — 2016 Update A Report From the American Heart Association. Circulation . 2016;133:38-360. doi:10.1161/CIR.0000000000000350
6. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National Trends in Ambulatory Oral Anticoagulant Use. Am J Med . 2019;128(12):1300-1305.e2. doi:10.1016/j.amjmed.2015.05.044
7. Glotzer T, Hellkamp A, Zimmerman J, Sweeney M, Yee R, Marinchak R. Atrial High Rate Episodes Detected by Pacemaker Diagnostics Predict Death and Stroke. Circulation . 2003;107:1614-1619.
8. Eikelboom J, Oldgren J, Ph D, Parekh A, Pogue J, Sc M, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med . 2009;361(12):1139-1151.
9. Hylek EM, Hanna M, Al-khalidi HR, Ph D, Ansell J, Atar D, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med . 2011;365(11):981-992.
10. Wallentin L, Becker R, A B, CP C. Ticagrelor versus clopidegrol in patients with acute coronary syndrome. N Engl J Med . 2009;361:1045-1057. doi:10.1056/NEJMoa1505949
11. Shih AW, Crowther MA. Reversal of direct oral anticoagulants: a practical approach. Hematol Am Soc Hematol Educ Progr . 2016;2(1):612-619.
12. Scaglione F. New Oral Anticoagulants: Comparative Pharmacology with Vitamin K Antagonists. Clin Pharmacokinet . 2013;52(2):69-82. doi:10.1007/s40262-012-0030-9
13. Antovic JP, Skeppholm M, Eintrei J, Boija EE, Söderblom L, Norberg E, et al. Evaluation of coagulation assays versus LC-MS / MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol . 2013;69(11):1875-1881. doi:10.1007/s00228-013-1550-4
14. Favaloro E, Bonar R, Butler J, Marsden K. Laboratory testing for the new oral anticoagulants: a review of current practice. Pathology . 2013;45(4):435-437.
15. Reilly P, Lehr T, Haertter S, Connolly S, Yusuf S, Eikelboom J, et al. The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol . 2014;63(4):321-328. doi:10.1016/j.jacc.2013.07.104
16. Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb . 2003;33(4):173-183. doi:10.1159/000081505
17. Samuelson BT, Cuker A. Blood Reviews Measurement and reversal of the direct oral anticoagulants. Blood Rev . 2019;31(1):77-84. doi:10.1016/j.blre.2016.08.006
18. Seyve L, Richarme C, Polack B, Marlu R. Impact of four direct oral anticoagulants on rotational thromboelastometry (ROTEM). Int J Lab Hematol . 2018;40(1):84-93. doi:10.1111/ijlh.12744
19. Zghaibe W, Scheuermann S, Munting K, Blaudszun G, Besser M, Ortmann E, et al. Clinical utility of the Quantra® point-of-care haemostasis analyser during urgent cardiac surgery. Anaesthesia . 2020;75(3):366-373. doi:10.1111/anae.14942
20. Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, et al. 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol . 2020;76(5):594-622. doi:10.1016/j.jacc.2020.04.053
21. Grottke O, Aisenberg J, Bernstein R, Goldstein P, Huisman M V, Jamieson DG, et al. Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. Crit Care . 2016;20:115. doi:10.1186/s13054-016-1275-8
22. Majeed A, Ågren A, Holmström M, Bruzelius M, Chaireti R, Odeberg J, et al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: A cohort study. Blood . 2017;130(15):1706-1712. doi:10.1182/blood-2017-05-782060
23. Goldstein JN, Refaai MA, Jr TJM, Lewis B, Goldberg-alberts R, Hug BA, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions : a phase 3b , open-label , non-inferiority , randomised trial. Lancet . 2015;385(9982):2077-2087. doi:10.1016/S0140-6736(14)61685-8
24. Demeyere R, Gillardin S, Arnout J, Strengers PFW. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Int J Transfus Med . 2010;99(3):251-260. doi:10.1111/j.1423-0410.2010.01339.x
25. Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, et al. Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.N Engl J Med . 2017;376(2):136-148. doi:10.1056/nejmoa1606424
26. Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Cott EM Van, et al. Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. Am J Hematol . 2019;94(6):697-709. doi:10.1002/ajh.25475
27. Pollack C, Reilly P, van Ryn J, Eikelboom J, Glund S, Bernstein R. Idarucizumab for Dabigatran Reversal — Full Cohort Analysis. N Engl J Med . 2017;377(5):431-441. doi:10.1056/NEJMoa1707278
28. Crespo-leiro MG, Amador RL, Granados L, Barge-caballero SMCDE, Segovia-cubero J, Rangel-sousa FGD, et al. Use of Idarucizumab to reverse the anticoagulant effect of dabigatran in cardiac transplant surgery . A multicentric experience in Spain. Clin Transpl . 2019;33(12):e13748. doi:10.1111/ctr.13748
29. Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med . 2019;380(14):1326-1335. doi:10.1056/NEJMoa1814051
30. Schulman S, Gross PL, Ritchie B, Nahirniak S, Lin Y, Lieberman L, et al. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors : A Prospective Cohort Study. Thromb Haemost . 2018;118:842-851.
31. Watson CJ, Zettervall S, Hall M, Ganetsky M. Difficult Intraoperative Heparinization Following Andexanet Alfa Administration.Clin Pract Cases Emerg Med . 2019;3(4):390-394. doi:10.5811/cpcem.2019.9.43650
32. Flaherty D, Connors JM, Singh S, Sylvester KW, Rimsans J, Cornella L. Andexanet Alfa for Urgent Reversal of Apixaban Before Aortic Surgery Requiring Cardiopulmonary Bypass: A Case Report. A&A Pract . 2019;13(7):271-273. doi:10.1213/xaa.0000000000001052
33. Levy JH, Welsby I. Andexanet Alfa Use in Patients Requiring Cardiopulmonary Bypass: Quo Vadis? A&A Pract . 2019;13(12):477-477. doi:10.1213/xaa.0000000000001115
34. Erdoes G, De Arroyabe B, Bolliger D, Ahmed A, Koster A, Agarwal S, et al. International consensus statement on the peri-operative management of direct oral anticoagulants in cardiac surgery.Anaesthesia . 2018;73(12):1535-1545.
35. Parasrampuria DA, Marbury T, Matsushima N, Chen S, Wickremasingha PK, He L, et al. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.Thromb Haemost . 2015;113(4):719-727. doi:10.1160/TH14-06-0547
36. Awtry E, Loscalzo J. Aspirin. Circulation . 2000;101(10):1206-1218. doi:10.1097/01.NURSE.0000524762.35753.23
37. Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, et al. Stopping vs. continuing aspirin before coronary artery surgery.N Engl J Med . 2016;374(8):728-737. doi:10.1056/NEJMoa1507688
38. Jacob M, Smedira N, Blackstone E, Williams S, Cho L. Effect of timing of chronic preoperative aspirin discontinuation on morbidity and mortality in coronary artery bypass surgery. Circulation . 2011;123(6):577-583. doi:10.1161/CIRCULATIONAHA.110.957373
39. Hansson EC, Malm CJ, Hesse C, Björn Hornestam, Dellborg M, Rexius H, et al. Platelet function recovery after ticagrelor withdrawal in patients awaiting urgent coronary surgery. Eur J Cardio-thoracic Surg . 2017;51(4):633-637. doi:10.1093/ejcts/ezw373
40. Hassan K, Kannmacher J, Wohlmuth P, Budde U, Schmoeckel M, Geidel S. Cytosorb Adsorption During Emergency Cardiac Operations in Patients at High Risk of Bleeding. Ann Thorac Surg . 2019;108(1):45-51. doi:10.1016/j.athoracsur.2018.12.032
41. Ranucci M, Bozzetti G, Ditta A, Cotza M, Carboni G, Ballotta A, et al. Surgical Reexploration After Cardiac Operations : Why a Worse Outcome ? Ann Thorac Surg . 2008;86(5):1557-1562. doi:10.1016/j.athoracsur.2008.07.114
42. Fröjd V, Jeppsson A. Reexploration for Bleeding and Its Association With Mortality After Cardiac Surgery. Ann Thorac Surg . 2016;102(1):109-117. doi:10.1016/j.athoracsur.2016.01.006
43. Mehta R, Sheng S, O’Brien S, Grover F, Gammie J, Ferguson T, et al. Reoperation for bleeding in patients undergoing coronary artery bypass surgery: incidence, risk factors, time trends, and outcomes. Circ Cardiovasc Qual Outcomes . 2009;2(6):583-590.
44. Biancari F, Airaksinen KEJ, Lip GYH. Benefits and risks of using clopidogrel before coronary artery bypass surgery: Systematic review and meta-analysis of randomized trials and observational studies. J Thorac Cardiovasc Surg . 2012;143(3):665-675.e4. doi:10.1016/j.jtcvs.2011.01.069
45. Mannacio V, Meier P, Antignano A, Di Tommaso L, De Amicis V, Vosa C. Individualized strategy for clopidogrel suspension in patients undergoing off-pump coronary surgery for acute coronary syndrome: A case-control study. J Thorac Cardiovasc Surg . 2014;148(4):1299-1306. doi:10.1016/j.jtcvs.2013.12.011
46. Stone GW, Clayton TC, Mehran R, Dangas G, Parise H, Fahy M. Impact of major bleeding and blood transfusions after cardiac surgery : Analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. Am Heart J . 2012;163(3):522-529. doi:10.1016/j.ahj.2011.11.016
47. Kapetanakis EI, Medlam DA, Boyce SW, Haile E, Hill PC, Dullum MKC, et al. Clopidogrel administration prior to coronary artery bypass grafting surgery: The cardiologist’s panacea or the surgeon’s headache?Eur Heart J . 2005;26(6):576-583. doi:10.1093/eurheartj/ehi074
48. Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha SP, et al. 2011 Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines * The Society of Thoracic Surgeons Blood Conservat. Ann Thorac Surg . 2011;91(3):944-982. doi:10.1016/j.athoracsur.2010.11.078
49. Valeri C, Khabbaz K, Sf K, Marquardt C, Ragno G, Feingold H, et al. Effect of skin temperature on platelet function in patients undergoing extracorporeal bypass. J Thorac Cardiovasc Surg . 1992;104(1):108-116.
50. Despotis GJ, Avidan MS, Hogue CW. Mechanisms and Attenuation of Hemostatic Activation During Extracorporeal Circulation. Ann Thorac Surg . 2001;72(5):S1821-31.
51. Levy JH. Discontinuation and management of direct-acting anticoagulants for. Am J Emerg Med . 2019;34(11):14-18. doi:10.1016/j.ajem.2016.09.048
52. Badhwar V, Rankin JS, Damiano RJ, Gillinov AM, Bakaeen FG, Edgerton JR, et al. The Society of Thoracic Surgeons 2017 Clinical Practice Guidelines for the Surgical Treatment of Atrial Fibrillation. Ann Thorac Surg . 2017;103(1):329-341. doi:10.1016/j.athoracsur.2016.10.076